| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Internal Medicine II, Medical University of Vienna, Vienna, Austria
2 Vacsular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Vienna, Austria
3 3rd Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
* To whom correspondence should be addressed. E-mail: johann.wojta{at}meduniwien.ac.at.
Plasminogen activator inhibitor-1 (PAI-1) plays a pivotal role in the regulation of the fibrinolytic system and in the modulation of extracellular proteolysis. Increased PAI-1 was found in atherosclerotic lesions and high PAI-1 plasma levels were associated with coronary heart disease. Smooth muscle cells (SMC) are a major source of PAI-1 within the vascular wall and PAI-1 was implicated in SMC migration, proliferation and apoptosis. We treated human coronary artery SMC (HCASMC) and human aortic SMC (HASMC) with the glycoprotein 130 (gp130) ligands cardiotrophin-1 (CT-1), interleukin-6 (IL-6), leukemia inhibitory factor (LIF) or oncostatin M (OSM). Only OSM increased PAI-1 antigen and activity production significantly in these cells up to 20-fold. OSM upregulated mRNA specific for PAI-1 up to 4.5-fold in these cells. HCASMC and HASMC express gp130, OSM receptor, IL-6 receptor and LIF receptor. OSM induced extracellular signal-regulated kinase (ERK) 1/2 and Akt phosphorylations HASMC. A PI3K inhibitor and a MEK inhibitor reduced Akt and ERK 1/2 phosphorylation, respectively and abolished OSM-induced PAI-1 upregulation. A JAK/STAT inhibitor, a p38 MAPK inhibitor or JNK inhibitor I did not inhibit the OSM-dependent PAI-1 induction. OSM enhanced proliferation of both HCASMC and HASMC by 77% and 90%, respectively. We hypothesize that if the effect of OSM on PAI-1 expression in smooth muscle cells is operative in vivo it could- via modulation of fibrinolysis and extracellular proteolysis, be involved in the development of vascular pathologies such as plaque progression, destabilization and subsequent thrombus formation, and restenosis and neointima formation.
This article has been cited by other articles:
|
|
 |
|
  M. Kurdi and G. W. Booz JAK redux: a second look at the regulation and role of JAKs in the heart Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1545 - H1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Kastl, W. S. Speidl, K. M. Katsaros, C. Kaun, G. Rega, A. Assadian, G. W. Hagmueller, M. Hoeth, R. de Martin, Y. Ma, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation Blood, September 24, 2009; 114(13): 2812 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hohensinner, C. Kaun, K. Rychli, A. Niessner, S. Pfaffenberger, G. Rega, A. Furnkranz, P. Uhrin, J. Zaujec, T. Afonyushkin, et al. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells FASEB J, March 1, 2009; 23(3): 774 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Keates, S. Tummala, R. M. Peek Jr., E. Csizmadia, B. Kunzli, K. Becker, P. Correa, J. Romero-Gallo, M. B. Piazuelo, S. Sheth, et al. Helicobacter pylori Infection Stimulates Plasminogen Activator Inhibitor 1 Production by Gastric Epithelial Cells Infect. Immun., September 1, 2008; 76(9): 3992 - 3999. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
